TY - T1的计算建模预测and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00930-2019 VL - 54 IS - 5 SP - 1900930 AU - Chachi, Latifa AU - Diver, Sarah AU - Kaul, Himanshu AU - Rebelatto, Marlon C. AU - Boutrin, Anmarie AU - Nisa, Patricia AU - Newbold, Paul AU - Brightling, Christopher Y1 - 2019/11/01 UR - //www.qdcxjkg.com/content/54/5/1900930.abstract N2 - Asthma is a heterogeneous condition characterised by chronic inflammation and airway remodelling. T2-mediated airway inflammation, characterised by interleukin (IL)-4, IL-5 and IL-13, has been the recent focus of pharmacotherapy, with a host of targeted biologic agents now available to clinicians [1]. The anti-IL-5 receptor agent, benralizumab, causes depletion of eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity in blood; however, the mechanism of action in the tissue is uncertain. Benralizumab has reduced exacerbations and improved lung function in clinical trials.Benralizumab leads to a reduction in ASM mass in asthmatic airways, which can be predicted using a computational model http://bit.ly/2OwNMBy ER -